STAT3 and osteosarcoma: Our data strongly support that the activated Stat3 pathway could serve as a therapeutic target in rhabdomyosarcoma and osteosarcoma cancers using a dominant negative Stat3 mutant or a small molecule Stat3 inhibitor, STA-21.